Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 266

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 19
Chunk 266
---
64                              189.37  
  Balance, October 31, 2023          2,216      $                     138.55      $                        96.06  
  Granted (i)                      591,460                              1.86                                1.36  
  Exercised                      ( 329,338                              2.22                                1.65  
  Balance, October 31, 2024        264,338      $                       2.55      $                         1.80  

  (i)      During the year ended October 31, 2024, the Company issued 591,460 RSU’s to consultants, directors and officers. The RSU’s vested with a fair value of $ 804,962 (2023-$ 91,589).  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  12.      Financial                        

  Fair Values  

Fair
value measurements are classified using a fair value hierarchy that reflects the significance of inputs used in making the measurements.
The fair value hierarchy has the following levels:

  Level                                                                                     

  Level                                                                                       

  Level                                                                                              

F-31

CLEARMIND
MEDICINE INC.

Notes to
the Consolidated Financial Statements

(Expressed
in United States Dollars)

  12.      Financial                                    

  Fair Values (continued)  

Assets
and liabilities measured at fair value on a recurring basis were presented on the Company’s statement of financial position as
of October 31, 2024, as follows:

                                                 Fair                                                                                                                     
                                                 Quoted                                     Significant      Significant                      Balance                     
  Short-term investment- shares                  $                             110,400      $                $                 –              $                  110,400  
  Short-term investment- Polyrizon Warrants                                    –                                               178,988                           178,988  
  Derivative warrant liabilities                                               –                                               3,519,702                       3,519,702  

Assets
and liabilities measured at fair value on a recurring basis were presented on the Company’s statement of financial position as
of October 31, 2023, as follows:

                                      Fair                                                                                                                    
                                      Quoted                                    Significant      Significant                      Balance                     
  Short-term investment               $                             86,112      $                $                 –              $                   86,112  
  Derivative warrant liabilities                                    –                                              4,310,